Copper-Associated Hepatopathy in Dogs: Welfare Management

Copper accumulation in the liver is a significant and often underdiagnosed welfare problem in Bedlington Terriers, Labrador Retrievers and other predisposed breeds.

Key Facts

Copper-associated hepatopathy (CAH) occurs when the liver fails to excrete copper normally, leading to progressive accumulation and hepatocellular damage
Bedlington Terriers have a well-characterised autosomal recessive mutation causing severe CAH; Labradors and Dalmatians are also predisposed
Clinical signs are often non-specific (lethargy, reduced appetite, weight loss) until liver disease is advanced
Copper-chelating drugs (D-penicillamine) and dietary copper restriction are the primary management approaches

Welfare Considerations

CAH causes progressive liver disease that is often silent until hepatic reserve is substantially depleted. Welfare impacts during subclinical disease include fatigue, nausea and reduced appetite that owners may attribute to normal ageing. Acute hepatic crises — including haemolytic anaemia from copper release — cause sudden severe welfare deterioration. DNA testing for Bedlington Terriers eliminates affected breeding stock and represents a definitive genetic welfare intervention for this breed. Early diagnosis through liver biopsy allows intervention before welfare is significantly compromised.

What You Can Do

Test Bedlington Terriers for the COMMD1 copper metabolism mutation before breeding
Discuss liver copper quantification by biopsy for any Labrador or other predisposed breed with unexplained liver enzyme elevation
Feed low-copper diets and avoid copper-supplemented foods in affected dogs
Administer copper chelation therapy (D-penicillamine) consistently — compliance is the limiting factor in management success